MAM
KRYS icon

Martingale Asset Management’s Krystal Biotech KRYS Stock Holding History

Martingale Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.72M Buy
7,311
+103
+1% +$30.8K 0.06% 323
2026
Q1 		$1.86M Buy
7,208
+2,702
+60% +$719K 0.05% 360
2025
Q4 		$1.11M Buy
4,506
+1
+0% +$210 0.03% 451
2025
Q3 		$795K Hold
4,505
– – 0.02% 537
2025
Q2 		$619K Sell
4,505
-631
-12% -$92.7K 0.02% 581
2025
Q1 		$926K Hold
5,136
– – 0.02% 483
2024
Q4 		$805K Buy
5,136
+1
+0% +$177 0.02% 522
2024
Q3 		$935K Hold
5,135
– – 0.02% 470
2024
Q2 		$943K Sell
5,135
-699
-12% -$117K 0.02% 456
2024
Q1 		$1.04M Sell
5,834
-5,853
-50% -$813K 0.02% 460
2023
Q4 		$1.45M Sell
11,687
-80
-0.7% -$8.87K 0.03% 364
2023
Q3 		$1.36M Sell
11,767
-301
-2% -$36.7K 0.03% 350
2023
Q2 		$1.42M Sell
12,068
-1,540
-11% -$157K 0.03% 351
2023
Q1 		$1.09M Hold
13,608
– – 0.02% 422
2022
Q4 		$1.08M Buy
13,608
+9,005
+196% +$668K 0.02% 431
2022
Q3 		$321K Buy
+4,603
New +$333K 0.01% 705
2021
Q4 		– Sell
-13,406
Closed -$700K – 857
2021
Q3 		$700K Buy
13,406
+6,900
+106% +$408K 0.01% 589
2021
Q2 		$443K Sell
6,506
-100
-2% -$6.98K 0.01% 619
2021
Q1 		$510K Sell
6,606
-100
-1% -$7.27K 0.01% 601
2020
Q4 		$403K Sell
6,706
-27,700
-81% -$1.38M ﹤0.01% 668
2020
Q3 		$1.48M Sell
34,406
-22,999
-40% -$999K 0.02% 508
2020
Q2 		$2.38M Buy
57,405
+32,605
+131% +$1.57M 0.03% 471
2020
Q1 		$1.07M Buy
+24,800
New +$1.3M 0.01% 658

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Martingale Asset Management's KRYS Position: Q2 2026 in Review

Martingale Asset Management increased its Krystal Biotech (KRYS) stake by 1.4% in Q2 2026, buying an estimated $30.8K and bringing the position to 7,311 shares worth $2.72M. The position accounts for 0.06% of the portfolio, ranked #323.

Martingale Asset Management first reported a position in KRYS in Q1 2020 and has held it in 23 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Martingale Asset Management held 7,311 shares of Krystal Biotech worth $2.72M as of Q2 2026.
  • Martingale Asset Management bought 103 Krystal Biotech shares in Q2 2026, an estimated $30.8K.
  • Krystal Biotech made up 0.06% of Martingale Asset Management's portfolio in Q2 2026, its #323 holding.
  • Martingale Asset Management first reported a position in Krystal Biotech in Q1 2020 and has held it in 23 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.